ClinicalTrials.gg
Not yet recruitingNCT07414199ED-Heme FCMUpdated Feb 17, 2026

The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department

A Phase 4 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate in Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes and Iron Deficiency Anemia Treatment, sponsored by Children's Hospital of Orange County. Not yet recruiting. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Children's Hospital of Orange County · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Planned enrollment
22nd of 57
150 · median 100
Started
2026
with 3 others
Phase 4
24 of 57
6 open now
Registered
54th of 57
by date
Lead sponsor
1 of 57
Children's Hospital of Orange County

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2026, is one of 24 in phase 4, and was the 54th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The goal of this project is to assess the feasibility, clinical effectiveness, and cost-effectiveness of IV iron therapy using ferric carboxymaltose (FCM) as a treatment for pediatric patients with iron deficiency anemia (IDA) in the emergency department (ED).

The primary objectives are to:

  1. examine and compare healthcare utilization and clinical outcomes of IV FCM use in the pediatric ED compared to historical cohort.
  2. determine the feasibility of IV FCM in the pediatric ED.

A secondary objective of this study is to evaluate if additional laboratory markers such as soluble transferrin receptor (sTfR) or reticulocyte hemoglobin equivalent can serve as potential surrogate markers for diagnosing and monitoring treatment response of IDA between oral iron and IV FCM.

By evaluating clinical outcomes such as the time to resolution of anemia, hospitalization rates and need for PRBC transfusion, assessing the feasibility of FCM implementation, and secondarily exploring potential adjunct markers for monitoring IDA, this study aims to fill the current research gap and potentially revolutionize management of IDA in pediatric emergency care.

03

Conditions studied

  • Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
  • Iron Deficiency Anaemia Due to Dietary Causes
  • Iron Deficiency Anemia Treatment
  • Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
  • Iron Deficiency Anemias

Keywords

  • Iron deficiency
  • anemia
  • ferric carboxymaltose
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 year to 18 years of age
  • Lab results indicative of anemia due to iron deficiency with between 6.0 g/dL-10.0 g/dL for age and gender
  • Patient is hemodynamically stable

Exclusion criteria

Exclusion Criteria:

  • Patients \<1 year or > 18 years of age
  • Patients with normal or Hb \<6 g/dL
  • Overt Bleeding (excluding menstrual bleeding)
  • Traumatic etiology for blood loss
  • Thrombocytopenia ( \<100k)
  • Active infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Newly diagnosed iron deficiency anemia

    Participants receive oral iron supplementation

    Drug: Ferrous Sulfate

  • Experimental
    Recurrent or refractory iron deficiency anemia

    Participants are randomized to receive oral iron supplementation or IV Ferric carboxymaltose

    Drug: Ferric Carboxymaltose (FCM)

Interventions

  • DrugFerric carboxymaltoseStudies of Ferric carboxymaltoseFerric carboxymaltose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants with recurrent or refractory iron deficiency anemia will be randomized to receive oral iron supplementation or IV Ferric carboxymaltose

    Also known as: injectafer

  • Newly diagnosed iron deficiency anemia participants will receive oral iron supplementation

    Also known as: fer-in-sol, slow Fe

06

What researchers measure

Primary outcomes

  1. Time to resolution of anemia

    days to normalization of Hgb with treatment

    Time frame: 6 months

  2. Need for blood transfusions

    Volume of blood transfused

    Time frame: 6 months

  3. Rates of Hospitalizations

    Number of patients with iron deficiency anemia enrolled on study and hospitalized due to their anemia

    Time frame: 6 months

  4. Re-presentation rates

    The number of patients enrolled on the study that re-present to the ED for ongoing care of their anemia

    Time frame: 6 months

Secondary outcomes

  1. Time spent in the Emergency department

    Length of stay measured, in hours, in the emergency department.

    Time frame: 6 months

  2. Adverse reaction to interventional treatment

    Side effects of treatment with iron

    Time frame: 6 months

  3. Treatment tolerability

    Adherence to oral iron therapy

    Time frame: 6 months

Other outcomes

  1. Changes in laboratory biomarkers

    Associated changes in soluble transferrin receptor and reticulocyte hemoglobin equivalent during treatment for iron deficiency anemia

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2026, 4 months later.

Of 43 non-industry phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 4 months is below that.

Counting every sponsor, half of 51 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Feb 17, 2026
StartEst.
Jan 31, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414199
Lead sponsor
Children's Hospital of Orange County
Responsible party
Maritza Ruiz (Physician Attending, Children's Hospital of Orange County) — Principal investigator
First posted
Feb 17, 2026
Start date
Jan 31, 2026 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 17, 2026

Study contacts

Manager, Clinical Research Programs
Contact
shelby.shelton@choc.org
714-509-3742

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion